Aquestive Therapeutics, Inc. (AQST) Operating Margin
- Operating margin · 12 months: Value -97.52%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -97.52% | Operating income / revenue. Period ending 2026-06-30. $-52.74M ÷ $54.09M × 100 ≈ -97.52% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -52.74M USD | Operating Income (Loss) |
| Revenue | 54.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 17.83M USD | Cost of Goods and Services Sold |
| Research and development | 15.89M USD | Research and Development Expense |
| Selling, general and administration | 73.11M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-52.74M | $54.09M | $17.83M | $15.89M | $73.11M | -97.52% |
| 2026-03-31 | $-55.89M | $50.27M | $18.37M | $16.04M | $71.75M | -111.18% |
| 2025-12-31 | $-71.05M | $44.55M | $18.55M | $17.19M | $79.85M | -159.50% |
| 2025-09-30 | $-55.79M | $43.40M | $17.24M | $18.91M | $63.04M | -128.56% |
| 2025-06-30 | $-52.60M | $44.13M | $17.17M | $19.65M | $59.91M | -119.19% |
| 2025-03-31 | $-41.18M | $54.23M | $17.14M | $19.71M | $58.56M | -75.94% |
| 2024-12-31 | $-30.77M | $57.56M | $17.87M | $20.28M | $50.18M | -53.46% |
| 2024-09-30 | $-21.10M | $58.90M | $18.03M | $18.25M | $43.72M | -35.83% |
| 2024-06-30 | $-15.19M | $58.36M | $18.39M | $16.18M | $38.98M | -26.03% |
| 2024-03-31 | $-19.45M | $51.50M | $20.48M | $15.49M | $34.98M | -37.77% |
| 2023-12-31 | $-15.10M | $50.58M | $20.83M | $13.10M | $31.75M | -29.86% |
| 2023-09-30 | $-21.90M | $48.06M | (m) | $14.49M | $34.01M | -45.58% |
| 2023-06-30 | $-28.38M | $46.52M | (m) | $14.53M | $39.09M | -61.01% |
| 2023-03-31 | $-36.93M | $46.54M | (m) | $16.25M | $47.31M | -79.35% |
| 2022-12-31 | $-42.07M | $47.68M | (m) | $17.48M | $52.88M | -88.23% |
| 2022-09-30 | $-43.02M | $48.08M | (m) | $17.60M | $56.05M | -89.49% |
| 2022-06-30 | $-42.14M | $49.90M | (m) | $19.10M | $55.72M | -84.44% |
| 2022-03-31 | $-35.89M | $51.98M | (m) | $18.16M | $53.27M | -69.05% |
| 2021-12-31 | $-34.68M | $50.83M | (m) | $17.05M | $53.48M | -68.22% |
| 2021-09-30 | $-38.66M | $46.90M | $14.41M | $17.07M | $54.08M | -82.42% |
| 2021-06-30 | $-44.47M | $41.88M | $12.99M | $19.61M | $53.75M | -106.19% |
| 2021-03-31 | $-37.56M | $48.21M | $12.06M | $19.19M | $54.51M | -77.91% |
| 2020-12-31 | $-42.89M | $45.85M | $12.96M | $19.89M | $55.89M | -93.55% |
| 2020-09-30 | $-37.15M | $55.12M | (m) | $18.52M | $56.78M | -67.40% |
| 2020-06-30 | $-34.37M | $59.28M | (m) | $16.32M | $58.70M | -57.99% |
| 2020-03-31 | $-53.45M | $48.73M | (m) | $20.63M | $61.05M | -109.69% |
| 2019-12-31 | $-52.67M | $52.61M | (m) | $20.57M | $64.34M | -100.11% |
| 2019-09-30 | $-55.12M | $53.01M | (m) | $23.20M | $66.57M | -103.96% |
| 2019-06-30 | $-53.32M | $53.86M | (m) | $22.67M | $65.20M | -98.99% |
| 2019-03-31 | $-67.31M | $56.66M | (m) | $22.51M | $82.60M | -118.80% |
| 2018-12-31 | $-48.93M | $67.43M | (m) | $23.11M | $72.26M | -72.57% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $73.89M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-113.00K | $66.92M | (m) | $22.13M | $25.08M | -0.17% |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |